So then, moving on to give you more of an overview of the genomic medicine working group, which was the sort of the grandparent of this particular effort now telling you about a working group of you. So the advisory council has two major working groups that I'm aware of, one of them you just heard from before lunch and now this one. And just to remind you who is on it, so this is the group and then Eric and Laura and I are sort of the ex-officio folks from NHGRO. The GMWG was set up about four years ago, shortly after the strategic plan was released, to help us in charting this area, particularly to evaluate and implement genomic medicine and review progress, identify research gaps, identify and publicize key advances. We decided we needed a series of meetings. We actually weren't sure it was going to be a series, but we knew we needed at least one and figured there probably would be others to help us explore this area and also learn who is doing this work, bring them together and form more of a community of effort. Facilitate collaborations and explore models for long-term infrastructure and sustainability. So as I mentioned, we've planned a series of meetings. These first three were in rapid succession in the first year or so after the strategic plan was released. Again, mainly to kind of develop collaborations and get people aware of what each other was doing and not duplicate what each other was doing, because there was a fair amount of siloing and duplication. Our fourth meeting was focused specifically on physician education, because I think everybody recognized that that was an area that needed to be addressed. Our fifth was trying to develop federal strategies. That was one that the gentleman you're going to hear from next managed to make it through for a period, and really asking our other agencies what should we be doing together in implementing general medicine. The global leaders meeting that I mentioned to you previously, in October we held one on genomic clinical decision support, and the report for that has gone in for publication. And then this most recent one in June was really kind of an overview. So the working group members said, you know, something that would be very helpful would be for us to take a step back and look at all of the programs all together and see how they fit together, where they could fit together better, and what the gaps might be. And just to kind of give you a feel for what's come out of these meetings. So our first meeting actually led to a separate workshop a few months later that we called ClinAction, and from that the clinical genome resource, or the ClinGen, was born. And so that was kind of a direct descendant, basically of that first meeting where people were saying, you know, got all these variants, we don't know what they mean. We all sit down in the room and try and hash it out, and it seemed to us that if people were doing that in separate rooms in 20 or 30 or 100 places around the country that we could organize and coordinate that effort and get it done much faster. The Emerge Pharmacogenetic effort also came in large part out of that first meeting where we recognized that Pharmacogenetics was a ripe area and that we could be working in one of our large consortia to be able to implement it rapidly. Our second meeting was on collaborations and that led to our Ignite program where we really are trying to take centers that are expert in this area and then try to have them disseminate to centers that really don't do genomics at all, so family health clinics, community health centers, military, VA, other kinds of places. Our third meeting involved payers. We really wanted to work with payers to understand what kind of evidence they needed in order to be able to support this kind of reimbursement for these kinds of tests. Our fourth on education led to the Inter-Society Coordinating Committee that you've heard about a few times since at this meeting. And the fifth one, I have dotted lines here not because I didn't want to imply that our fifth meeting produced CMS FDA or the Air Force, but what they have a nose, what they did produce were closer collaborations with those groups in looking at ways that we can share information and collaborate to improve implementation where it's appropriate, not just willy-nilly. The fifth one also led to a trans-NIH working group within NIH. This is something we discussed with the Institute leaders at one of their strategic planning forums and they basically said, you know, we need to also know, everybody needs to know what's going on within NIH and it was that group that we drew from when we put together the SGS10 planning group. Our sixth meeting, which was the Global Leaders Meeting, led to a global consortium called the Global Genomic Medicine Consortium, or G2MC. It is jointly hosted with the Institute of Medicine and it will have another meeting in Singapore in November and there are a series of areas that groups are collaborating in and also working with the Global Alliance for Genomics and Health, which is much more of a research effort, it's more of an implementation effort. You've heard about that before, so I won't go into it much with limited time, but out of that group came the SGS10 meeting that you just heard about. Our seventh meeting in clinical decision support led to a much stronger collaboration with the Institute of Medicine Genomics Roundtable and there was kind of a plan hatched for a soup to nuts program in Genomics Clinical Decision Support at our meeting that is now being implemented in the Genomics Roundtable, so that's very exciting. And then our eighth meeting was just held in June. The objectives of it were, as often is, kind of where are we going sort of meeting, so reviewing our portfolio, identifying gaps, identifying related programs among other centers and ways that we can work together, research needs for ourselves and our partner agencies to pursue. And then we always try and one of the reasons that we do these programs as large collaborative programs is that they can have an impact on the field and sort of pushing it forward or pushing in a direction that no single investigator can have by themselves no matter how good they are. And then examine potential methods for assessing the impact of these programs. So we decided to kind of focus on the six programs that are the major genomic medicine portfolio parsing. You've heard these described before, so I'm not going to go into detail about them, but they're here. And our undiagnosed diseases, newborn screening, clinical sequencing, emerge the IGNITE program and dissemination and then the ClinGen resource. And then we also had a series of related programs that we wanted to hear from and have members in the room, some of them in the very basic realms, some in informatics, as you see here with GSIT, ENCODE was there. Representatives from the ILM, Ron Tave-Wolf, some from the NCI clinical trials that are genomically driven, et cetera. So a large number that we tried to bring together and see where we had the opportunities. And then we asked for summaries from each of them. This is one from the clinical genome resource. It's basically a summary that describes who's involved, what the mission or the objectives are. Here's another one for newborn sequencing, a third one for the centers of menelium genomics. And in these we asked for just two pages to describe the objectives, what the funding period is, the working groups, the resources and tools that they've produced, publications, obstacles, and the approaches to meet those obstacles. And all of those are stored and available on the website for this meeting, which if you search Genomic Medicine 8, or if you just go Genomic Medicine Activities, the website for the meeting will come up, and then you can find these meetings summaries. And we're still referring back to them. They're very useful to have. One of the things we asked them to do, as I mentioned, was to identify their objectives. And then we kind of looked across them to see what their objectives, particularly in the focus programs, that are really quite common across them, because we would expect them to have some that would be in common. And as you might expect, these are very closely aligned with the goals of our division and the goals that the Genomic Medicine Working Group has outlined for itself. So integrating genomic data into patient care, incorporating actionable variants into the electronic medical record, particularly with using clinical decision support, educating clinicians and patients, assessing the outcomes, defining and sharing how best to do this in best practices, promoting interactions and collaborations, translating implementation outside highly specialized centers. And while this is Ignite's special role, actually several of the programs are doing this currently. There were also some that were pretty much targeted or unique to a given program. So the UDN is very heavily emphasizing improving genomic diagnosis and facilitating research and undiagnosed diseases. But Insight and Seizure do a little bit of that kind of work as well. Only Insight is looking at newborn care. Electronic phenotypes are something that is unique to Emerge, but is needed by all of these programs really. Identifying variants related to complex traits are showing a few of them as well. Pharmacogenetics is pretty much the domain of Emerge and Ignite. Looking at penetrance is pretty much Emerge alone. Standardizing clinical annotation, assessing actionability with mainly Insight and ClinGen, and then creating genomics-enabled learning health care systems where we can actually improve care in a real-time way. Something that Seizure and Emerge and Ignite are really focusing on. And we also identified barriers that face multiple programs. Lack of an evidence base was one we knew four years ago. It's one we have now, and it's probably one that will be with us for as long as we're in this area. The need for common data elements came up repeatedly. It's something that we want to try to encourage across the programs. Assessing the frequency and impact of variants, particularly in ancestrally diverse populations. Something that is a particular problem. And as Eric mentioned earlier today, that Ben's had an entire workshop on focusing specifically on why is it so hard to get information in ancestrally diverse populations when we must have it. Rapid evolution of evidence on variants. So how do you deal with the changing levels of evidence? A variant that you thought yesterday was benign. Now, a report comes out, and it looks like, oh, it might not be so benign. A few more reports come out, and well, gee, it's pretty clearly pathogenic. How do you deal with that in relating to patients and clinicians? The current limited usefulness and interoperability of clinical decision support systems. So you build it in one hospital system, and it works, hopefully, in that one hospital system, but nowhere else. Regulations that impede return of results have really gotten in our way, in many ways, with the research efforts that we're doing. And we're working with our colleagues in the regulatory field to try to address those, but that's going very slowly. And it is having an impact both on the research and the clinical care. Need for cloud computing is growing as the sequence data grow. So does the need for better ways to manipulate the data and transfer it to move it around when you do. Reimbursement policies and regulations, I mentioned earlier, I think, and a particular need for a bedside back-to-bench research. So how can we stimulate that virtuous cycle where we find something at the bedside and can take it back and really investigate it? We set up a series of panels. These were the panel areas, and we asked them to then address a number of questions. How important is this topic in this area? What programs do we have addressing it? What are the gaps? What could be the synergies in the training opportunities? And then we asked each of the Genomic Medicine working group members to lead one of those and very much appreciated their efforts in doing that. There were a series of recommendations that got a lot of discussion. I may be heavily discussed as a little too strong, but I tried to pull out those that seem to be recurring just to kind of share them with you. And again, sorry not to have gotten these out to you sooner. They are in the report, and we'll post these slides so that if you want to refer back, you'll have them. But generating evidence was an area that everybody agreed was something we needed to do much more of data sharing and improved phenotyping, particularly standards for phenotype description that you could use from model organisms to humans so that you can go back to the bench when you've seen something at the bedside. A lot of interest in patient-oriented ontologies, so ways that patients can enter information on what their child has or what they have, what their symptoms might be, and that could still be translatable in ways that cases could be picked up around the world and linked together. Identifying and carrying out innovative studies, particularly engaging basic sciences more actively in planning our programs because we don't have that voice at the table very often when we have this table, but we need you to speak up more in terms of how we can do the science better. An interesting idea was to add family history to a large-scale sequencing effort so that we might end up with 20,000 people who had both a rigorous family history, not one that took weeks to put together, but something using some of the more up-to-date software tools that can be done relatively rapidly. If you had that on 20,000 people with their sequence information, imagine what you could learn about the added value of family history and how you need family history information to interpret particularly in rare sequence variants. Studying the impact and consequences of changes in variant annotation, facilitating implementation commons was something that was very attractive to a number of the groups putting tools into a common place where people could then use them and share their experience using them. Health disparities, and again, we discussed some of these last week and you'll be hearing about them more, but looking at specific health disparities, research questions related to genomics and implementation, developing dedicated programs for non-European ancestry populations and increasing patient engagement, education and training is always an area that is needed, potentially joint training opportunities or best practices for clinician education. One of the things that we did with this meeting was to take, we had about 50 recommendations and we thought, well, why don't we ask people to sort of tell us what their top 10 is? So from the ones that I showed, I pulled out about 20 of them to report to you, but we then through our, Duke University was working with us on this workshop and so they sent out a little survey and said, just tell us what your top 10 are and rank them from one to 10. And then we kind of averaged those just to see which were those that tended to come to the top and you'll notice that up here there are a couple that are really quite popular and then there's maybe a little bit more of a shelf down here at 10 or 11. So I just pulled these out to show you what the top ones were. And the top number one was measuring outcomes of value to patients, clinicians, payers and then a whole list of other stakeholders. So regulators, et cetera, et cetera. How can we learn what outcomes are important to these groups so that we can add them to our studies it couldn't, it might not be very difficult to do and produce information that is much more useful to them. The family history tool came in second to us at 3.5, identifying types of evidence to collect and share across programs, accelerate rapid genotype phenotype explorations. One of the big concerns was that a lot of these explorations take a very long time and if you have a sick baby in the neonatal intensive care unit or if you have someone else who is really quite desperately old you don't want that process to take months or years. Suggestion was made to consider cooperative sequencing groups to gather information about sequencing much like the cooperative oncology groups that the NCI has funded at the, you know basically the budget of this institute many, many times over per year. So we couldn't do anything quite that grand but at least something to consider. And then a number of others that I just sort of show here facilitating coverage through evidence development identifying payers needs something that we are really struggling with. You know, what is it that payers really want to see? Not that we're trying to get everybody to pay for these things. We want to understand what is appropriate to be paid and what isn't. And so how can we learn what evidence to generate for that? Post-marketing studies, similar to pharmacovigilance studies but for genetic testing. So can you kind of gather information from people who've had genetic tests on what their outcomes are and how they use that information? Some agreed upon nomenclature, variant definitions and allele identifiers that will help us with some of the trading information back and forth like the pharmacogenetics star allele system which is very cumbersome and very difficult to work with. HLA is another area where nomenclature is a major challenge. Are there other ways to work on that? Computable guidelines to put into clinical decision support systems. Clinical trials of the added value of whole genome sequencing to more limited testing. So the question that we're doing in Emerge right now, we can afford basically a 100 gene panel and if we did a whole genome sequence compared to what would be the risks and the benefits we might identify a whole bunch of stuff you don't know what to do with and you just run up costs without any added benefit. On the other hand, you might find somebody who's at risk for carbamazepine toxicity that you didn't know and they might be about to get that or a related drug. So our plans for follow up immediately are to engage basic scientists. This came up over and over. We need basic scientists at the table and involved in developing our programs. So we've had a lot of emphasis on this sort of pathway from the bench to the bedside and we really need to go back and be sure that the function is explored and other things are explored in the laboratory. Areas that seemed like they would benefit from this included phenotyping that was compatible with model organisms to promote that kind of research. Variants on myclature was one function to help us with clinical annotation. So those are the things that we are going to pursue and that will be sort of a focus of our ninth meeting which will be held next April. Pursuing infrastructure needs, there were a lot of suggestions that were really kind of infrastructural, develop knowledge bases of what's going on in genomic medicine, a variety of other things. The implementation of commons, common data elements, those are things we're going to have to struggle with a bit because they don't really seem to lend themselves necessarily and we would welcome your advice to funding opportunities where we say somebody develop common data elements or increase patient engagement in that. But they're things we need to think about a bit. And then comparative effectiveness research, I may have put this on anticipating the next talk to come but we did hear something that would be very useful would be a whole genome sequencing versus targeted panels. Another would be whole genome sequencing with or without family history and large enough numbers to be able to draw some conclusions. So these are the people that were involved in putting this together and many thanks to them. And then back to you. So we welcome your comments on our recent activities and advice on the priorities that we've outlined. And I've asked Carol Bolt and Howard Jacob to comment. Carol, do you want to go first? So of course these are all very broad ranging giant areas of activity that were discussed and outlined especially at the last genomic medicine meeting. And we've talked a little bit on our phone calls about how we can most effectively work together to move forward genomic medicine. And I think that, I think there's a number of things in the priorities that came out and we're still discussing whether those are the right priorities. So really interested in people's comments about whether or not they feel like the ones that came out of the survey. Which I forget, Teri, how many people responded to the survey? It was a small number. So we had about 88 at the meeting and 35 responded. Yeah, that's always a challenge, right? We hold these meetings and then you ask for feedback and you get feedback from a very small number of people and that ends up being your recommendations and priorities. So part of the benefit of bringing it out to the group like this is, is that a bias sense? Is there general agreement with these priorities or not? And just with respect to the planning for GM9, you want me to comment on that as well. So as Teri said, one of the themes that emerged a number of times during GM8 was this integration of basic science and how that can effectively promote and advance genomic medicine. And it goes back to what Eric was saying earlier this morning about the fact that we have all these variants come out in these genome sequencing projects and we don't know their biology. We don't know what they do. And to effectively integrate that information into genomic medicine, we have to functionalize them. And so this virtuous cycle that Teri had the slide on that, we want GM9 to kind of focus on that virtuous cycle. How can we better integrate, especially the arc that goes from the patients back into the model organisms and how we develop the models themselves, right? When we talk about models, that means so many different things to so many different people and even being able to communicate effectively about what a model is and what it means is important to do. So that's going to be, currently that's going to be our focus for GM9. Howard? Howard, did you want to talk? Yeah, so I think that's a great summary. I would only add one additional point to what Teri and Carol have mentioned, and that is that connection at the basic research level. We need to also be able to do it, and Teri did say this, but we have to do this much, much faster because as we're doing more and more of this clinical sequencing, it's right at the edge of care slash research, and we're finding these variants of uncertain significance. So not only do we need to think how to functionalize it, but how do we do this fast enough to provide information back to the patient or to the physician in order to try to affect care? So that's all I had to add, but I thought it was a good summary. Great, thank you. Comments from the group? I just want to echo what Carol said. I mean, I think that we've spent GM1 through 8 on sort of looking at other communities, and as we were planning for GM9, it was one community that we really haven't engaged, and that's our basic science colleagues and everybody around this table, from the most clinical to the most basic, recognizes that the potential for that virtuous cycle functionalizing, I like that word, variants of uncertain significance is a huge problem, and there are many, many other, I'm sure, opportunities that the clinical data sets that we're generating should offer to the basic scientists, and there are other things that basic science should be offering to us besides just telling us whether a particular SNP is functional or not, and that's why we have to have that interchange. Just, it's a great comment, and this goes back to what I was talking about in terms of models. So we're used to thinking about models of understanding the basic biology, but there's also model systems to look at therapy outcomes, right? And so those can be completely different models, but we tend to lump them all into the same thing, and I think this meeting could help us start to tease some of those things apart so that there's really good communication. And I might note that we have that scheduled for April 19th and 20th, I believe, that's a Tuesday and a Wednesday, I think, in 2016. Not quite sure if it'll be in Bethesda or if it's in a more central part of the country, but we would hope that folks will put that on their calendars, and Eric, I know you'd love to come to Bethesda, so if we have it in Bethesda, you'll be there. Yes, we hold it in Houston, you won't be there. So great. Any other comments? Great, thank you very much. If not, then I'll go ahead and introduce our next speaker, if that's all right.


What's up everyone? It's your girl Kenzie here from Leighton Sports Cards and I'm ripping a personal for Gianluca Bruno We've got a 21-22 Panini prison basketball first off the line hobby All right best of luck Gianluca. You see your first off the line sticker right there Here we go. Pull a gold shimmer. How about that? Pulsar of Torian Prince You're right Randy Bye for Tyrese Maxie David Johnson, yeah, Sean's a dolphin fan Killin me man. They're killing me. Silver Jaylen Noel. We've got red Angelo Russell T. Wolfs That is 257 of 299. Hey, I don't know soon move rookie base and Jason Preston rookie We have nine out of 30 a blue shimmer of Jared Jackson Jr. Triple J action there and we've got purple Six of 99 Jonathan Kumminga for the Warriors There you go dubs nice one there on the Kumminga We'll mag that one for you Shingoon Ben Wallace. Oh, I thought you said got carded off Silver cherry rose here Isaiah Todd hyper rookie Isaiah livers rookie base Got red wave Isaiah livers rookie pistons blue has on white side for the jazz 141 of 199 Just Maddox Lamello Banton rookie Jeremiah Robinson Earl rookie Silver rookie of Santi Aldama Grizzlies Firework Silver John Morance. We've got a Scotty Lewis on the silver rookie auto Hornets Jaylen Green rookie base and Robert Covington. All right second half Red wave of Zion Williamson Pelicans hyper rookie Jaylen Suggs nice one there Just Maddox Kauai Cameron Thomas rookie Steve Nash Looking for another auto here Silver Jaylen Brown. We've got red on the rookie color match Isaiah Todd wizards 257 of 299 Bear got Scotty Barnes rookie base Ray Allen and in Jonathan Kumminga base Red wave of Tyree's Halliburton Kings Purple ice Kevin love for the calves 71 of 149 Mine set LeBron Jaren Butler rookie Silver Aaron Gordon. We've got a John Stockton on the hyper Somatic honest Jaylen Johnson rookie Tray Murphy the third We've got one of one black shimmer Kelly Ubre junior Hornets There you go, Gianluca nice on the black shimmer there one of one beautiful black shimmer There you go old mag this one for you widescreen hyper Yannis We've got to 25 Tony Parker on the mojo sensational signatures Wow, what a pack Nice one there that is 22 of 25 We'll mag that one as well Jordan pool and Santi Aldama rookie last pack Silver Marbury, we've got fearless silver of Shaquille O'Neal Keon Johnson and Pete Maravich Alrighty Gianluca that will do it for your box. Congrats again on those hits in one of one And we'll be getting this right out to you


Due to flooding that has devastated some areas of Bielsa State, Bielsa United, Bendel Insurance, El Canemí Warriors and Doma United will once again have to wait until November before competing in the Nigeria National League Super Four playoff. The season-ending event was rescheduled to hold between October 25th and 29th at the Samson Siasya Stadium, Yonegoa. After floods forced, the initial date of October 16th to 22th to be changed. Amar Ignes, the head of the media and communications at Nigeria National League, released a statement announcing the new dates change. The four clubs earned promotion to the Nigeria Professional Football League and finished top two in the southern and northern conferences of the Nigeria National League to qualify for the playoffs. Hello, hope you enjoyed the news. Please do subscribe to our YouTube channel and don't forget to hit the notification button so you get notified about fresh news updates.


So in our previous video, we talked a little bit about the modern history and the evolution of public relations over the last, you know, couple hundred years from the 1800s through to today. And so we've covered where we came from. I want to talk a little bit now and look into the future a little bit. Check our crystal ball and see if we can identify what may be coming down the pike for public relations practitioners in the future. So with that in mind, let's take a look at some future trends in public relations and just some key questions, things we need to be aware of in public relations that may be coming up for us in the in the next evolutionary stage for public relations. So when we think about key questions, first of all, one big one is probably already sorted out is the growth and impact of digital media. Just a huge explosion of digital media that we didn't have in 20 years ago. Really, this was not a factor nearly as much as it is today. And in fact, if we look at the social media usage in the United States, adults for adults in the United States, social media usage in 2005 was about 7 percent of the adult population in the United States. In 2018, it was 73 percent. So this dynamic explosion, exponential growth in the usage of social media, for example, in the United States as part of digital media, just just went through the roof. Another area of importance that can kind of characterize this growth force, the percentage of Americans who get some portion of their news from social media or have some portion of their intake, news intake from social media in the United States in 2012 that represented 49 percent of the population, which is pretty big. I mean, that's a lot of people getting at least part of their news intake from social media and in the span of just those eight years though, since then and we moved to 2020, we see that that number grows to 71 percent of American adults who get some portion of their news intake from social media. That's just incredible. Digital media is having an enormous impact on the entire world and public relations is not immune to that. We have to embrace that and really determine how we can best utilize digital media for growth and impact in the public relations industry as well. We're also seeing an expect to see more of an emphasis on measurement and ROI. So measurement, meaning some quantitative way to determine what impacted this public relations effort, this public relations campaign, that this work in public relations have on our bottom line. How do we measure that quantitatively? It's not just a matter of what does it feel like? It used to be just kind of in some ways you just say, well, that seemed like it went pretty well. Now, now we need to have some sort of way to quantifiably measure the impact and have that as part of our objectives and our goals as built into that public relations campaign. How are we going to measure this in a quantitative way? You know, in a very specific, quantitative way. And then also along with that, then focusing on return of investment. That's ROI. ROI is just return on investment, return on investment. So in other words, what are we getting out of this? You know, in a very specific, very quantifiable way. In fact, ROI has this formula where you just very simply divide net profit. So what is it that you gained in net? What is it that you you profited? The organization profited from this in a quantitative way. Divide that by what you spent, you know, divide what you earned by what you gained by what you spent, multiply that by 100. That gives you your percentage of ROI. So it's got that very specific formula. And organizations are looking for this now. This is again, part of the evaluation process for public relations has to do with these specific quantifiable methods for measuring and identifying return on investment from a public relations effort or public relations campaign. We're also seeing the integration of public relations and marketing. Again, I mentioned this before. We spent a lot of time defining between, you know, the difference between public relations and marketing and advertising, and they are different. They are very different. They have different functions, different objectives, different purposes, but they are also very much tied together for many organizations. So, so really seeing more of an integration between partners and partnership between public relations and marketing and even advertising in there as well. So how are they working together? Even though they have different functions, different objectives. A lot of times really how do they work for an organization together to meet those singular objectives of the organization? So we're seeing more integration and a future trend is the integration between the public relations and marketing function working together in partnership. Some additional key questions we need to have in mind as we look to the future of public relations, the intersection between public relations and corporate social responsibility or CSR. Corporate social responsibility involves a lot of different things. But basically what are the responsibilities? You know, we identify, you know, what are the responsibilities of citizens, for example, as a citizen of your community and of the United States or whatever country you're living in. What are your responsibilities as a citizen? How what are you responsible for in terms of dealing with other people and maintaining your property and so forth? What are your what are your obligations as a citizen of that of that of that community and of that of that state of that country, whatever. And we're recognizing that organizations now have the same types of responsibilities, in a sense, right? We have organizations have a responsibility to the publics that they serve.  But you also have responsibilities to the public around you, the publics that you serve, your customers, what you're providing them and also to the world around you to not be environmentally damaging, for example, right, to do your best to to help, you know, maintain a healthy global environment for us and to be ethical, to be fair to to your resources wisely and with good stewardship and so forth. So so how does public relations factor into all that for these organizations? That's where we're seeing more of that intersection of public relations playing a role, not just in strategy and not just application but but executive leadership decisions when it comes to corporate social responsibility. What are our responsibilities as an organization and how can we best meet those things and fulfill those responsibilities? So you're seeing more of, again, interaction in the intersection between public relations and the area of corporate social responsibility. One thing we really have to do a better job of in public relations and I think there's a real understanding of this and there've been some efforts but still much, much more to do in this area is diversity and inclusion.  Lots of people of color and minorities and women have done great things in public relations, but it's, you know, limited enough that it stands out because we have not as public relations as a field has not done a very good job of of, you know, really improving diversity and inclusion. And that's important for a couple of different reasons. First of all, I mean, just, you know, again, that social responsibility since we have the responsibility to be inclusive as a field and to really be represented well by people of all backgrounds and ethnicities and cultures and all those different types of things, right? But in a more practical sense, beyond just the ethical responsibility, it's important for a variety of different reasons, including things like how can you, as a public relations advisor, an organization or part of an organization, how can you expect to reach an audience if you're not represented in your organization by people from that audience? You know, how can you expect to speak to people from these minorities if you are a group of middle-aged white guys? How can you really understand the best way to reach and engage that audience if you're not represented, if you don't have that representation in your organization? So we need diversity for that reason, just in a very practical sense. We also need diversity for the, talk about diversity of thought and diversity of ideas as well to get out of these kind of boxes that we've been in, where we have these homogenous people of this, you know, similar background, similar, similar cultures and things. You're going to get a very limited scope of ideas with that. So you really need that diversity in public relations to help enhance the diversity of thought and the diversity of ideas and the diversity of leadership and just in terms of representation. It's a very important, in a practical sense, very important thing that we need to improve upon in the immediate future. And it's certainly in an ongoing sense as well. But this is something that needs to be a priority in the field of public relations is increasing the diversity of not just a personnel, but diversity of thought, diversity of ideas and all those types of things. So that's something in the future, in the very near future, in the immediate future and in the long term future that needs to be improved in the area of public relations. One other key question that we're going to have to answer is public relations folks, is this idea of globalization? You know, since we have this world now of digital media and we really have a broader audience, you know, organizations are multinational now. They are worldwide organizations are working all across the globe because we can, we have that kind of reach now. And so public relations firms need to be thinking outside of just their community and into, you know, a larger scope. This idea of globalization, which again can come back to diversity and inclusion. And it involves all of those types of things. But really we need to be thinking globally now and how is this going to impact the organization that we're working with or representing or whatever. How is this going to affect that organization on a global level? Not just on a local level, but now our audience is really the world. So we need to keep that in mind and have that sense of globalization. How do we best manage that? How do we best utilize that and capitalize on that as public relations practitioners? So, you know, this again just offered a little bit of a glimpse into that crystal ball. And these are more questions and answers though, right? We need to these are things we know are coming and that we need to have an answer for in the future for public relations. So it's going to be up to that next sort of evolutionary group as we expand upon this to identify what are the best answers for these key questions as we look at the future of public relations. If you have questions about this or about anything related to public relations, history, the future and so forth, please feel free to email me. I'd love to hear from you there. In the meantime, I hope that you will be thinking about these things as somebody who's potentially going to be involved in public relations in the future. These are things we need to think about now so that we have an answer for them as we move forward.


The following is a presentation of TFNN The Trader's Edge with Steve Rhodes All now toll-free at 1-877-927-6648 or internationally at<PHONE_NUMBER> The Trader's Edge Now Steve Rhodes Good afternoon folks. Welcome to the March 30 at the wonderful Wednesday edition of today's Trader's Edge show. I'm your host TV, Perseverance Rhodes who absolutely knows that each of us should always be pioneers of our future versus prisoners of our past. Hope everyone out there's having a great day Hey, let's make sure we have an extraordinary one of the easiest way to do that Just to always remember that life is happening for us not to us That's right We do not make that one little two-by-four shift means we can find the gift in every set of circumstance that life is gonna toss at us Now today you and I we're gonna go check out the circumstance of these markets We're gonna go figure out what those bulls and bears what those buyers and sellers are communicating to you and I just pass one O'clock in the afternoon. I want you to know I'm absolutely grateful for your presence here More important than that and that's this during this next 60 minutes I'm here to serve you so feel free to pick up that phone You can dial on an<PHONE_NUMBER> and if you can't dial in we've got you covered there, too You can always let those fingers do the walking that means go ahead and send me an email send it to Steve at tfnn.com And inside the subject heading, please put radio show question Of course and aside our Tigers didn't well any in every ping will do so let's go ahead and get this show started on Wonderful Wednesday, of course. This is Tiger finance a news network. I'm Steve Rhodes Welcome to the show right now. You get all US indices trading the downside Now is off 95 S&P's down 22 Nasdaq 164 Russell's off 17 semis down 54 trend is off 184 The largest percentage mover is a semis down one and a half percent To the upside you've got the gold up 21 bucks 19 38 is his prince Silver's up 42 pennies 25 16 is what it is printing lights we crude up 271 106 95 is the last trade natural gas Is up 19 cents? It's really 4% 552 there and a 30-year treasure up 21 ticks 149 19 is the print now lead the charge dollar-wise to the upside you've got Lulu lemon 40 bucks 11 percent Aberdeen standard Palladium is up about 5% or 11 bucks Biontech is up 9 and chains. That's nearly 6% crowd strikes 7 that's 3% so the downside It's restoration hardware off 46 bucks 12% Amazon down 39 or 1% booking holdings 34 one and a half percent Mercado Lear Bay off 27 bucks 2% Shopify down 25. That's about 3 and a half percent We did have a couple of requests. Why don't we get to those right away? Now we'll just simply go into the general markets. We have one request one from yesterday They didn't pick up on so let's go take a look at those and the first request was to take well Actually, there's three requests. One is Tesla Somebody want to take a look at the Xl y Joey want to take a look the Xl y and Hector and Patty We didn't get to their request yesterday take a look at the Xl f Let's get all three of those in and we'll get the markets out here So we take a look at Tesla Tesla trading above the top of its daily weekly and monthly profiles out there So all of that looks good That means we need to go switch over to our other set of charts out here and see if there's any kind of a topping signals Or anything that Dan from Boston needs to be aware of so we begin by taking a let's see that work Yeah, that worked. Okay, so now what do we know so on a monthly basis Dan You've got price trading above the green oscillator and change line So it's neutral because it has a confirmed roadsman to mitigate or top neutral to bullish is what we would say or what I would say Same kind of pattern set up inside the weekly above the profile which we discussed above the green oscillator change line It's got a roadsman to mitigate a signal. So really kind of neutral to bullish price should move higher go test those eyes However, the confirmation of that Dan will come from the daily time frame chart It's on a daily time frame chart much like the indices out here or many of the indices not all of them Tesla formed a TD 9 count topic completed that pattern yesterday did that on the bar following bar number 9 now the cool aspect about that We know where the high is that and what we know is that if there's a close above that high not a test of the high Not a spike of the high but a close of the high, which is 11 14 77 Then Dan that'll give you the signal that price going to make its way back to the highs The oscillator and change line here has changed colors So that really should signal to us that price that line should catch up to each other now We don't know if it's going to be a sideways movement while that oscillator and change line rises where the price is going to pull back As well as the oscillator and change line rise We just don't know what combination there is but the combination That's present for the pattern that's present right now suggests that that's what the move should be Well, that's the case. We should see some topping signals on the intraday charts out here. Well 195 minute chart and not so much not yet the 130 minute time frame chart No topping signal yet. It has a possibility to form a TD 9 count But it still hasn't taken out the higher high of this pattern, which is bar number five in that high out There is 11 14 77 so price does have to spike above that to get that however The 65 minute chart does have a TD 9 count top so that's really the one to take a look at and follow and Right now price would need to close below 10 65 83 to give you a signal that there's a chink in its armor out There and that chink could take it back to the 998 level That's the breakout level of the 65 minute chart and 986 happens to be the TD 9 count daily Osset and change line so I would watch a 65 minute chart for our signals out here But otherwise it's similar to the general market. So in fact as long as I'm here on this screen I'll just change over we'll go take a look at the NQ right now and as we take a look at the NQ As I can find it out here What we're going to see is basically something similar and the similar is if you look at the daily timeframe a TD 9 count If you look at the weekly chart so Tesla stronger on the monthly basis and the NQ because on the monthly base here for the NQ Price is below that Osset and change line in the case of Tesla Stronger than the NQ because price was above its monthly green Osset and change line the weekly here prices above that And that's what gives me the strongest period of pause with regard to this TD 9 count topping signal that we have And the reason is is because from an intermediate term standpoint using the monthly or the weekly timeframe chart price Really should have found resistance that this was just a countertrend rally and not that it still can't be but basically the ideal set up The ideal set up would have been price stopping at that Osset and change line as it did last week now The week is not over. It's only 1 13 in the afternoon And so we can't really totally make the call but we're going to communicate to you what it's communicating to us right now But if price did close back below that 14807 ish level out there come Friday afternoon Boy, that would be a big tell right now We don't have that tell and we don't have anything that's really broken down on a 30 minute chart Not any big signals there 60 minute chart no real key levels of support breaking so It looks like it unless something some news event Takes place here in the next couple of hours Maybe it's something that occurs overnight that sets off these TD 9 count patterns that we've got in the NQ The ES many and several of the indices out there But it is the weekly charts out here that give a Stevie pause because I was just going to make our Call from an intermediate term standpoint as to what the NQ is going to do and I was just using a weekly chart What I would be telling to you right now is that the NQ wants to continue higher We don't do that because we're not ignoring the daily signal that's out there So that gives you a general idea of the markets overall. Let's go back now. We've just have a few seconds here Let me get back to the tab if I can find it real quickly And we did have requests to take a look in the side of the Tigers den here. That was the XL Y I believe I hope I've got that right. Let me come back and see Where was that put in here? XL Y that was for joey D. So let's let this populate here joy What I'll do is I'll leave the XL Y on the screen here You're the Tigers den and hey folks everybody should join the Tigers den go to the homepage at tfnn.com You can sign up for a buck one dollar Mortimer for a full year So we'll leave these charts up. You'll get to take a look at it and enjoy maybe in your mind You can tell me what is it that Steve he's going to say about the XL Y Great Steve Rhodes started his trading career as a student almost 20 years ago And the student has now become the master Steve won the prestigious timer of the year award in 2018 and barely missed that mark again in 2019 finishing at number two for the year an amazing accomplishment Steve Rhodes is Committed to sharing his techniques and knowledge with anyone who wants to learn and he shares his vast amount of trading knowledge Every day in his mastering probability newsletter Steve's award-winning newsletter Mastering probability is delivered every trading day with updates throughout the afternoon sign up for Steve's market newsletter Mastering probability and you'll receive access to seven of Steve's educational webinars Absolutely free at tfnn all our newsletters come with a 30-day money-back guarantee So you have absolutely nothing to worry about visit tfnn.com and try mastering probability 30 days risk-free today tfnn educating investors What's separating you from the most successful men and women on Wall Street? That's right Information having all the information gives us the perspective We need to place the right trades at the right time the TAS profile scanner is the premier market profile base scanner Powered by its acclaimed task proprietary algorithms this feature rich scanner Instantly filters over 2,500 plus global financial markets such as stocks ETFs commodities futures and forex This powerful suite of tools Leverages instant trade filtering and strategy formulation to show you emerging trades Before they happen for a limited time you can save $100 off your first month by using the promo code upgrade And you still get a 30-day money-back guarantee So you have nothing to risk Level the playing field with the TAS profile scanner which you can find under the services tab at tfnn.com Sign up today Sharpening your skills as an investor is like getting better at playing a musical instrument You have to practice sure, but you also need excellent instruction from experts at tfnn You'll get advice and guidance from the authority and technical market analysis And it's not just dry tedious text either tfnn airs live Financial content streamed live on tfnn.com and tfnn's YouTube channel with Tiger TV Live every market day from 8 30 a.m. To 4 p.m. Eastern for free Each host is an experienced trader and gives their take on the market while taking calls and questions live from around the world From the moment the market opens until the closing bell sounds Tiger TV has eight different shows with expert hosts to help You make the right moves with your money watch online at tfnn.com or on tfnn's YouTube channel and become the investor You were born to be tfnn educating investors 1-877-927-6648 Internationally at<PHONE_NUMBER> Good back up folks So we're take a look at the xly that is the consumer discretionary sector and I think the question was just to take a look at it So when we do look at the xly looks different than the nq that we looked at looks different than tesla And what I mean by that is if we take a look at the daily time frame That's what we've got up on the chart first of all this bottoms with wave number seven that is letter g and erosement Diminuator signal that was on February 24th now just make an observation here. It is kind of interesting What else happened on February 24th? Does anybody out there know that inside the tiger's den? What else took place on February 24th when basically the US stock markets most of the indices made a bottom Does anybody know somebody out there's got to know what took place on February 24th out there of significance And yet our US stock market here has a bottom absolutely flip that was the date that Russia invaded Ukraine And that was the you know not my birthday Duffy, but thanks for asking We got to wait for September for that one but so In any event on that day here with regard to the xly you've got two bottoming signals Does two bottoming signals mean a stronger than one? No, it does not at least that's not what I've been able to determine just yet But in any event out here What we had is we had a TD nine count pattern Went ahead and topped on the trading day of March 23rd right as Joey Reddus price was moving right into its bearish structured daily profile So just clearing that is a very bullish outcome And that's what took place three days ago on March the 28th on Monday price closed above that and negated the TD nine count It closed above there's nothing more bullish than a failed bearish pattern Well, here you got the failed bearish pattern of the TD nine count plus combined with the bearish structured profile So sellers were unable to deal with the momentum of buyers In fact the volume on this trading day, even though you can't see it here on the white background chart Exceeded the volume of that TD nine count high that swing point out there now Many might say that that forms an a to b equals CD to the upside I'm not in that camp the reason I'm not in that campus because a retracement was only 18% Doesn't mean that price won't go higher out here But we don't need the a to b equal CD pattern in order to help us gauge where price is likely targeting Unless there's some other topping pad that forms between now and then and the target out here should be 209 39 now here's the deal if the S&P and the end obviously this is one of the sectors inside the S&P this should hold up the best Of a or one of the sectors that should hold up well just simply based upon these patterns if the move lower Let's say there is a move lower. We have the tops out there the ES the NQ And if there is a move lower You got the outside and change line here that has changed colors where price should find support and this is where you want to be a buyer Potential buyer of the xly would be at 184 11. It could be at 186 62 But typically would be at 184 11. That's the center of that Bearish structured profile out here The only thing to suggest that price might pull back is that that changing color on the OUL and the other indices Otherwise the signal here for the xly for its daily time frame is to head higher now What are the other time frames tell us about the xly? Weekly above the top of its profile that was also bear structured profile does weak does then till Friday out here But right now it's looking pretty good on the monthly chart the resistance levels 195 16 That's basically where the top of the profile is that which is really 192 222 and the Oscillator and change line no topping signal on the 195 You've got a TD 9 count on the 130, but price is holding support green oscillator change line 65 and has a TD 9 count top but price holding support So so far support is held on this but you know the xly the consumer discretionary will just simply be it's a it's a small waiting Or small, you know, it's not it's not one of the large weightings inside the S&P 500 So it's going to be subject to what the larger S&P is likely going to do but otherwise so that's what the xly looks like there was some questions here to take a look at Let's see here because they can get away from me pretty quick inside this little chat room out here and Where was one one? I think was to take a look at Apple And was there anything else? No, it's the xly and then I think the last thing inside the den was to take a look at Apple so let me punch that chart up on the screen here Let's go see what this is doing my recollection is Apple on a daily basis has a TD 9 count top as well So coincides what we're looking at inside the markets just waiting for these charts here to populate There we go. So as we take a look at the daily time frame of the xly you'll see yesterday Was it's TD 9 count up again? The beauty of that is if there's a close of my yesterday's high that high by the way is a 179-01 then we would see price get back to its all-time highs and that's in the 183 ish range out there So you want to watch that green outside or red outside and change line changes colors topping pattern You know the game plan, you know the rules here basically we should see price that line catch up to each other That's a daily time frame for Apple. What do we have here for the larger time frame? Well in the weekly basis price right now is above the top of a new profile that is forming this week That says it wants to move higher You've got a TD 9 count top on the monthly but price above that green outside and change line That says it wants to move higher. So the the real key here is the daily chart With regard to the intraday time frame charts the only topping well There's topping pattern for the 65 and for the 30-minute chart But no levels of support breaking the key level I'd say inside of Apple if the market is going to crack or croak Then you would see Apple close below 174 15 if you get that then that's going to really really be the signal moving to the 170 14 level now that number don't use that to be exact That's the outside and change line on the daily time frame You can use 170 415 because that was the TD 9 count breakout level for the 65-minute chart So that's what the charts for Apple look like out there. Did I get to everything? I believe that I have we got to XL y and Duffy Thanks for posting the holdings inside their Amazon Tesla Home Depot McDonald's Nike Lowe's Target Starbucks booking holdings and TJ max making up the top entities out there and it looks like that's 2340 far 51 for a I mean, that's a 60 70 percent of the of the men and the reason he posted that there Was simply to say hey you really should look at what's going on underneath the covers and certainly the top You know, I'd say the top eight or ten Charts are the top eight or ten holdings with inside there to really get a feel for what the XL or what the XL y is doing Request here. Let's see. There's a request a private request. I see that Steve please show charts on f t r i so let's go ahead and put up f t r i That is as John says etf holds large stakes in BHB Rio and Valley So our pleasure to do that for you John So let's just give this a moment to populate and then okay, and then we've got a request also to take a look at Rivian so very cool. So we're just a you know, you guys I'm just learning how to navigate this new discord tool out here So we take a look at f t r i What our signals here show and I'm just gonna quickly go to so on the monthly timeframe John This is bullish price is above the prior swing point There's no topping signal if anything there's need to be equal CD to the upside up here If we look at the weekly chart, I'm just gonna expand this out on the weekly time frame You know quite a way this had a TD nine count top that got negated and In basically one day that was the February 11 So this is a strong momentum move to the upside John We take a look at the weekly timeframe chart. So the monthly and weekly look very good What's a daily chart telling us a daily chart shows us what? Shows us that it negated a wave number seven. That's letter G out there Price today if price closes above today the high from March 25th that high is what a 1661 You're at 1663 the daily roadsman dominicator top will get negated But even if it doesn't its signal is neutral to bullish out here So the daily the weekly and the monthly particular symbol FTRI all suggest higher price John, I hope that helps you all we come back from this break. We're gonna go take a look at Rivian our IVN Having fun trading the markets But having trouble finding like-minded individuals to discuss your trading and investment ideas with become an apex Predator in the trading markets and join the Tiger's Den trading room only at TFNN comm The Tiger's Den is an exclusive trading room where successful traders from around the world come to exchange trades and ideas Join the den and surround yourself with these sharpest minds in the trading world Subscribers to the Tiger's Den are also the first to have their questions answered live on air and can privately chat with our TFNN hosts live during their shows Interact with other Tigers and Tiger's as they share trading ideas news analysis and discuss the market action all trading day Subscribe to the Tiger's Den risk-free with our 30-day money-back guarantee and become part of the TFNN trading community TFNN educating investors You could be making money off the stock market and if you're already making money off the stock market You could be making a lot more check out TFNN and Tiger TV and get expert investing advice To give you the power to control your financial future go to TFNN comm and find the newsletter for you whether you're into trading gold Metals futures currencies or options you'll get advice and analysis to help you seriously get ahead TFNN also features trading services with a 30-day money-back guarantee for new subscribers as well as TFNN's Tiger Den trading room trading software and educational webinars for all trading levels and make sure you check out Tiger TV for TFNN.com or TFNN's YouTube channel for live financial content from 8 30 a.m.. To 4 p.m.. Eastern on market days Stop watching on the sidelines while other people get rich and become the investor you were born to be TFNN educating investors TFNN is excited about our new software charting program the art of timing the trade charts in Collaboration with Tom O'Brien and using his best-selling book the art of timing the trade your ultimate trading mastery system David White has programmed an Outstanding piece of software that will complement any traders methodology using this first of its kind program the art of timing the trade charts allows You to scan thousands of stocks for Fibonacci formation setups including Gartley's ABC's Butterflies and much more the art of timing the trade charts is designed to help you when scouring the markets for stocks Just beginning to form the trading patterns that many investors spend days weeks or even months Searching to find and right now we're offering licenses available at only $79 a month we are so confident that you're gonna love this new charting software that will even give you a 30-day Unconditional money-back guarantee don't miss out on this incredible new piece of software get your copy of the art of timing the trade charts today By visiting TFNN.com This segment is brought to you by think or swim for more information Just click the think or swim banner on the front page of TFNN.com Welcome back folks to Chipper Symbol RIV and that's for Rivian and it's up on our screen out here, and it definitely has bottom It formed a weekly Rogement Dominicator signal a couple weeks ago. We'll put this up on our chart No, it's not enough data and generate any kind of market profiles So we don't have those we can see the Rogement Dominicator signal on a weekly time frame So that says let's go take a look at the daily time frame that a daily time frame confirm that bottom and it did Rogement Dominicator and TD9 count on March the 15th prices above its daily profile So price should now go target 59-14 and pricing close about 59-14 the TD9 count breakdown level This is going to give us a change in trend signal a change in change in trend signal to the upside would then suggest to move To the 66-54 level you got a short-term topping signal On the 65 minute and it looks like the 35 are the 30 minute charts going to give us that Well, we just started Well, we did know it gave us a 130. Okay, so you've got two topping signals out here But that might just be priced pulling back the test support areas in the support area here We'll be looking at 52.95 below that would be $50 and 13 cents But on a bigger picture if you're asking did Rivian form a bottom the answer there is yes But I buy into it now probably not it's too close to resistance that 59-14 area with price being at 54 36 out there, but it should get to that 59-14 area So I do hope that helps you out the next question. Well, let's go take a look at XLF for Patty and Hector hopefully they're listening in or maybe listen to the archive And I believe was the XLF that they had written in about that I didn't get to yesterday It was late in the show. So let's see if we can get this here to populate. So on a monthly basis for the XLF What do we know? You've got a what a roadsman to indicator top out here But price above that green oscillator and change line and above the top of its profile So Hector the neutral for that the signal for the monthly time frame neutral neutral to bullish The weekly chart has a roadsman to indicator top But here it is still bearish because price is found resistance at the 39 64 level That's a green oscillator and change line on a daily time frame As this was forming a bottom. Was there a bottom pattern that we can see out here? And the answer is no doesn't mean that didn't bottom just means I don't have one now prices back inside the daily profile and The oscillator and change on a change color. So price should go target at 3867 level That's what you're looking at or looking for you'd like to see a test and rejection of that green Oscillator and change line that would be the next potential buy point at the same time That's occurring you'd like to see some type of short-term bottoming signal We don't have a short-term bottoming signal right just yet However, the XLF on a 30 minute basis for me is in bar eight right now So it could form a bottom at around the 3906 level its breakout level Again, this is bar number eight that it's forming bar number nine will be complete by 230 so by three o'clock if the XLF is gonna bottom and have a little bit of a bounce That would be the pattern that you be looking at for it again That's the XLF the 30 minute could be a TD 9 count bottom out there But otherwise it looks like larger term larger term or not larger term Longer than the 30 minute time frame chart price should go target that daily oscillator and change line So Hector patty. Thanks much for waiting I do hope that that helps you out if that is in fact what you were looking for the next question here coming in from a Dan F and Dan says looking for an entry into CMC So let's go ahead get CMC fired up here CMC is what? CMC let me look at some other charts here. That is Commercial metals and your question was Dan looking for an entry point into CMC So it's got a new daily profile that formed today. It's bullish in structure and the the the Target area or the buy area potentially is between 3984 and 40 30 71 That is the bullish structured level of the daily profile on a monthly basis No topping signal in fact that they get any kind of topping signal suggests price should move higher the weekly Price should move higher it's above its oscillator and change line and the top of its weekly and the top of its weekly profile The daily time frame out here for CMC. Do we have any kind of a topping signal? So The answer is no, I don't have a bearish reversal candle even to confirm an a to b equal CD pattern to the upside But nonetheless watch for the support area. You're looking for an entry 3984 40 30 71 And ideally you'd see some type of bottoming pattern on one of the shorter term time frame charts 30 minutes 65 minutes Maybe one 30 or so out there So that's why I'd be waiting for being patient. You might get there a relatively quick But the daily and the weekly charts here for CMC Dan look very good. Thanks so much for writing in next question coming in from Well, it's like a Jeff near Philly and please take a look at BG FV FV not familiar with that one. Not that I'm familiar with all of them I just don't recall seeing that signal. So let's go to BG FV and See what this actually is big five sporting goods Corp. The question is please take a look at the stock You got long yesterday. Oh So it's pulling back today. We need to go figure out. What is it doing? So yesterday what it did here? Jeff was it got right up and it did close above the TD 9 count breakout level of 1907 but you know the game plan We need to see two consecutive closes in order to confirm a breakout So that being said what price is likely going to do is pull back to the 1695 1721 area on a monthly basis out here Price is trading into the support area of its bullish structure profile between 1075 and 1375 I don't have that. I've had a topping pattern on the weekly I don't have a bottoming signal on the weekly chart and that says that longer term price could be pulling back to 916 so be careful because the weekly chart well the weekly chart exercise a consulate as a new profile out here And price right now is consolidating within it. So watch 1488 to the downside and 1961 to the upside What else can I see here not much so It just looks like price wants to move lower for this instrument and that that lower should be in the 1694 to 1721 level. So Jeff, I hope that that helps you out. Thanks much for taking the time to write in Michael P wants to take a look at hell Steve. How does PBR look paps blue ribbon? So let's go take a look at PBR, which is not paps blue ribbon And because I'm sure that Michael P doesn't drink paps blue ribbon, but he does drink Petroleum Brazilliero Petrobras You know, I totally screwed that up, but it is what it is now. What is PBR actually doing out here? so what you can't see is the Descending trend line and rising trend line first of all go to I'll show you those momentarily the monthly chart looks bullish Price has moved to 1684 the weekly chart looks bullish But price is consolidating with inside its weekly profile needs a close here Michael P above 1468 that's what you're looking for the daily time frame chart doesn't have a topping signal But there's a descending trend line that price ran into I'll show you that momentarily the 195 minute chart as a roadsmen Dominicator signal key level support there is 1371 don't know the price getting it back there. Your question is How does PBR look as an investment? Do you see an entry? You're already in maybe some of the holdings? I don't know you've listed those I can't go through all of those so I Would what here's what I would do you up towards resistance On that weekly chart. You're really kind of neutral there Wow You know, I'd rather you buy this on some type of retracement and that retracement be 1445 1435 1435 1445 and where I'm going with that as a 30-minute chart That would be the bullish structured profile area out here But I don't have anything right now Michael It says the price is gonna get back down there So as I look at these charts, and that's why I was pausing a bit I don't have any signals here to really suggest that this thing can go lower if there was any signal to go lower Maybe it's from the 15-minute chart and I would say 1415 1450 would be the area Mike P Thanks much writing in and I hope that that helps you out. We'll be right back Are you in the market for buying or selling real estate in the Bay Area including the surrounding St. Petersburg Tampa and Clearwater markets? Tiger real estate LLC is a firm that has extensive experience in the Tampa Bay area Whether you're looking to sell your current property for maximum value or you're in the market for a second home Or investment property Tiger realty has the experience across all areas of real estate in the Tampa Bay area to help buyers and Sellers make the most informed decisions across all price levels from the price You should be paying per square foot in certain up-and-coming areas to the type of cash flow Investment properties are capable of creating Tiger real estate can help you make the best decision when it comes to all areas of the Market before you make one of the biggest decisions of your financial future called Tiger real estate LLC today at<PHONE_NUMBER> or email us at tiger at tfnn.com That's<PHONE_NUMBER> call us today The technology around us is changing every day with so much happening. It can seem impossible to keep up with all the information David White's investment newsletter the technology insider is designed to give you all the information You need to understand the technology that shapes today's markets and tomorrow's future David White has made his living staying on the cutting edge of technology His weekly newsletter will give you specific recommendations for value tech stocks as well as entry prices Target prices and stops to set for each trade Dave delivers his weekly newsletters every Friday with updates throughout the week You can get the technology insider at tfnn.com for only $37 and 50 cents Sign up for David's newsletter the technology insider and get an inside look at everything the technology sector has to offer Try at risk-free today with our 30-day money back guarantee Tfnn educating investors Biotech is booming but for how long whether you think the biotech bull has room to run or has run its course trade LA BU or LA BD Directions daily S&P biotech three times bull and bear ETFs Visit direction investments.com Slash biotech today an investor should consider the investment objectives risks charges and expenses of the direction chairs carefully before investing the Perspective and summary prospectus contain this and other information about direction shares to obtain a prospectus or summary prospectus Please contact direction shares at<PHONE_NUMBER> the prospectus or summary prospectus should be read carefully before investing an Investment in the funds is subject to risk including the possible loss of principal the funds are designed to be utilized only by sophisticated investors such as traders and active investors distributor four-side fund services LLC Don't forget you can listen to tfnn live on your mobile device 24 hours per day Go to tfnn.com and hit watch Tiger TV That's tfnn.com and hit watch Tiger TV Now folks, let's go to Peter in Park City Peter. Thanks for calling. Thanks so much for holding. How are you today? I Great Steve. I had a question for you and this may be beyond like obvious On the NYSE oscillator We put in highs back in January, I believe and then we are above the 150 again just recently Yet the market is making significantly lower, you know a lower high that it did back then Can we garner anything from that? We all went back to just work this week or so I I wouldn't you saw the the I Wouldn't go back and use the January data and take a look at because actually We made a higher high and that advanced the client oscillator reading just a few days ago back on the 18th of March and that reading was much higher than the ones that you were looking at in January So, you know, that's that's really not that's my question. No, basically, okay Is is there a kind of a negative divergence within that itself? Can we read anything from that or no? I just when I saw your charts before with the oscillator unchanged As I just happened to notice that you know, we're kind of basically up at the same levels yet The market's not near the same level. I Don't know I don't I haven't done a Enough I haven't done any research on that to to make that determination So I understand exactly what you're saying and what are you saying folks here's look We have a negative divergence the advanced client also they're making higher highs So in and price is making the lower highs out there. Does that mean anything? So I've got enough tools to really interpret what it means right now and there still is a little There's a divergence a small divergence, you know on a closing basis the advanced client oscillator peaked on March 18th But 223.24 is reading and then yesterday We got up to 213 21. So you still have declining tops there with rising price That combined with oh, I've got the wrong page of my apology. Give me a moment here. Sorry about that Peter and everybody else They're kind of like same. What are you talking about Steve? Oh, so here's what I'm talking about Here's the chart that Peter and I are discussing and so here what he was talking about is this junior area Well, my curse is that in this panel area and here he said hey look we've got a higher high out there So this has been rising in essence if we were to draw a trend line Our price has been declining and a question there is and I suppose then the assumption would be if that's a negative Divergence that should lead to higher prices. Is that basically what your your thought process is? No, I'm thinking that the prices will come down and so like we've just we've gotten to a point where Basically we've gotten let's see. I'm now I'm looking okay. There we go. Oh, actually that is interesting from just Monday The change you know, let me see the chart Yeah But if we take a look at just the current information the current information says we still Have a divergent pattern with a lower high in the advanced client oscillator higher high in price And then we switch from this chart here to the white chart that I believe that I was showing before And that's the actual chart for the New York Stock Exchange and when you get that divergence folks We like to see is some kind of topping pattern Well, in fact yesterday was the TD 9 count top for the New York Stock Exchange as long as price is not closed What yesterday's high this suggests that it the New York Stock Exchange should pull back to 16577 So the divergence is Suggesting and the pattern the TD 9 count pattern suggestion that pulled back now If price just gets back and test and rejects that green oscillator and change line That's actually a bullish signal for the market And if we go back to the advanced decline oscillator It's signal is actually bullish for the market longer term not short term with the Shoot didn't mean to do that Sorry about this. Yeah, I'm not able to multitask that well. It's amazing I'm actually can able I'm actually able to talk and look at a screen at the same time out here But because we got to hire because we got above the plus 150 level just getting above plus 150 Typically means over time in the future. We're gonna see higher. We're gonna see higher prices them Then where that advanced decline oscillator high occurred And so this this suggests that we should see higher price out there That's the reading of it of the advanced client oscillator All right, I think it was just one some clarification there if there was anything to be read from it Yeah, your specific question yours. Yeah, your specific question I I don't have I've never done a study to be able to answer that but maybe maybe you could do that for me Maybe Thanks, Steve. Have a great day you too and thanks so much for calling and for holding The last question after last go we got a few minutes here. The next question that has come in is from Jack Was it Jack? Yeah, it is Jack. So Jack writes is fairly long See what's up on my screen out here at the black background screen? So let me just switch over here for a moment as I start reading so Jack says Good day, sir He must be talking about my dad because my dad would be sir not Stevie Just starting just trying to learn basics been listening to your show for the past two weeks I think it's great. My good friend Greg in New Hampshire told me I should make sure I listen to you Wow, Greg's a good guy my question probably two elementary four-year listeners now There's no question. That's too elementary for any of us. So no worries of no time though We're gonna make the time I need to do a lot more. Okay, how how many stocks should I attempt to watch for trends as a novice? Well, that's a good question.  I'm gonna switch over to the white background screen And I'm gonna switch charts out here Even though some people might say that it's beauty when you're a novice here because you're just really learning So if I was just teaching somebody brand new into this I would say what you're going to first focus in on are the futures contracts so that's the first thing you want to be able to get access to if you want to learn technical analysis and the reason is because the Futures are trading 23 plus hours of the day and what I do why Greg perhaps told you to watch the show is I Trade patterns there are patterns that repeat over and over and over and over again now That doesn't mean that every pattern works. We learn from failure and learning from failure is to most certainly use stops And that means position sizing but with regard to instruments that you're trying to learn and you're trying to understand trends I would focus in on the futures contracts and you want to be able to get access to the short-term time frames If you subscribe to different folks here at TFN, you're gonna learn a ton In my case you can subscribe for 29 days and app access to a bunch of videos that will help to educate you But I would start with the futures contracts because they are the ones that provide us with the most consistent signals out here Many people will tell you that they're thinly traded overnight Doesn't matter whether thinly traded or not what we're looking for is price discovery and we're looking for those patterns those patterns being the TD 9 count you're seeing here what we're talking about right now today's a TD 9 count tops are out inside the yes Many in the NQ and inside the Dow even though it doesn't have a TD 9 count back to negated it It ran right into resistance where price of broken down. Now. These are not things these price breakdown areas and breakout levels These are nothing that I'm pulling out of my, you know, what they're specific with regard to Rules it's all rules based system out here and they really work There's not a single Individual with inside of TFN that I know of or even inside our den that would have chosen 35-244 as the resting place or the stopping place for the Dow equity future contract yet. That's what took place yesterday So that would be the first place that I would start to answer your question and darn if I didn't just lose your email But I'll find a way to get it back out here Steve wrote to a TFN and try to see if we could sum up Jack's questions or questions when we get back from this break Sharpening your skills as an investor is like getting better at playing a musical instrument You have to practice sure but you also need excellent instruction from experts at TFN You'll get advice and guidance from the authority and technical market analysis, and it's not just dry tedious text either TFNN airs live financial content streamed live on TFNN.com and TFNN's YouTube channel with Tiger TV Live every market day from 8 30 a.m. To 4 p.m. Eastern for free Each host is an experienced trader and gives their take on the market while taking calls and questions live from around the World from the moment the market opens until the closing bell sounds Tiger TV has eight different shows with expert hosts to help You make the right moves with your money watch online at TFNN.com or on TFNN's YouTube channel and become the investor you were born to be TFNN educating investors You might think that if you want to be successful at trading in the stock market You're going to need a crystal ball after all it's impossible to predict the future, right? Like any endeavor in life before you decide it's impossible get some advice from the experts You might find that it's not so impossible after all for daily market overviews that give you direction on the key indices Selective stocks and commodities subscribe to the opening call newsletter at TFNN.com The opening call newsletter is written by Basil Chapman Creator of the trading methodology known as the Chapman wave the Chapman wave up down sequence gives you an edge in Identifying price turns finding the peaks and valleys and stock prices get the opening call newsletter by Basil Chapman and your inbox Every day first time subscribers also get a 30-day money back guarantee if you're not satisfied Let us know and you'll get a full refund within 30 days of signing up TFNN.com educating investors Are you looking for a secured investment which pays you on a monthly basis the target first mortgage program? Maybe the program for you the best rate on a five-year CD in the country right now according to bank rate comm is paying 1% per year or $1,000 per a $100,000 invested the target first mortgage program pays 7% per year paid monthly on secured high value Buildable properties in st. Petersburg, Florida the investment is for four years paying 7% per year a $7,000 per 100,000 dollars invested your investment is secured by high value real estate in st. Petersburg, Florida Your investment can be anywhere from 100,000 to 500,000 you want to make 1,000 per year on a hundred thousand dollars invested a 7000 per year on a secured Tiger first mortgage the Tiger first mortgage program Maybe just the program for you the Tiger first mortgage program pays 7% per year paid monthly for more information You can call<PHONE_NUMBER>. That's<PHONE_NUMBER> Don't forget you can listen to TFNN live on your mobile device 24 hours per day Go to TFNN.com and hit watch Tiger TV. That's TFNN.com Then hit watch Tiger TV Come back folks. Jack my apology. I somehow accidentally deleted your email But I think it should be on my desktop out there, but I do believe you're asking about Disney Specifically, so I'll just give you the review for Disney You'll see the chart patterns we take a look at once referred to as a TD 9 count when Disney topped out here on a monthly basis It was March of 2021. It was a TD 9 count when Disney bottom It was in January of 2022 or even this month if we got to a lower there We did get to a lower low this month here And so now you have a TD 9 count bottom on the monthly time frame price should go target 160 to 164 The weekly time frame chart generated a rogment to indicator bottom It did the week of March 18th. You're inside a new bullet structured profile as long as price closes above that red line Price should continue higher 151 68 is a target That will be the case as long as price does not close below 137 12 137 12 is the bottom of its weekly profile now That's above the actual bottom that formed out here But that would suggest if you close below that that you're going to go retest lows from March 18 You have a TD 9 count bottom in Disney here that completed on the trading session of March 14th prices moved higher It's the reason why I'm we're concerned about the NQ and the ES who've got TD 9 count tops You see this pattern repeat over and over again now what Disney did yesterday was confirmed in a to be equal CD The upside you can't see that on the white background screen What I can share with you is the volume yesterday inside of Disney was 11.2 million shares the swing point that have passed at 8.5 million shares The swing point is one label with this be so now there's a confirmed a to be equal CD to the upside in Disney That should take us up to the 150 level. Well, the TD 9 count breakout area is at 148 65 So that really becomes its target out there So I believe that what you were sending to me might have said that people were saying There's all kinds of problems in Disney or what have you right now The charts are saying that it is bottom and that it wants to move higher So it's not a matter of which stocks do you focus on it's a matter of learning the patterns out here That's if you're gonna listen to my show and the information I provide to and you want to be able to do the same Which I'd love for you to be able to do the same It's the reason that I do the show out here Learn these tools and learn the other tools learn the tools of Basil listen to the next hour your favorite polar bear David White is up next Talbot Brian Hilt teach y'all about the a to be equal CD pattern and I'm Steve Rhodes And I'll be back with you tomorrow one o'clock sharp have wonderful Wednesday folks. Thanks for joining us


Monogamy or non monogamy polyamory open relationships closed relationships That's what this book the truth by Neil Strauss is all about Neil Strauss, of course, is the author of the famous pickup book called the game And the truth is his journey from trying to figure out how to be in a committed relationship He was a bit of a geek and then he became a bit of a player and then he met a wonderful woman And then he cheated on her and now in the book he's trying to figure out why he cheated on her And to make amends and to figure out if monogamy is for him That's pretty much the book. It's a good book Neil Strauss the truth I'm going to go to the end part. I'm not going to tell you how the story ends but There's a part here on page 419 of the end He says that he's come to realize that there's no so-called natural way to be in a relationship The whole idea that we can study the past or other cultures to determine what's right for us today is ridiculous Because nearly every society tells a different story of mating and sexuality And every point of view can be supported with evidence from some other tribe or species There isn't just one true and proper way to love to relate to bond to touch Any style of relationship is the right one as long as it's a decision made by the whole person and not the whole in the person So that's very good. I really liked that part. The book is, you know, like once he cheats on his long-term girlfriend He goes off trying to try polyamorous relationships That's having like two even three girlfriends at the same time He goes to swingers clubs and sex parties and he details his journey through that And the emotions, some of them amazing, some of them not so amazing And then ultimately he culminates in what happens at the end of the book Which I won't tell you what happens, but if you just do a Google search of Neil Strauss in the IELS-TRA US You can probably see what happened, but if you want to read the book first I would encourage you to do so So if you are struggling with monogamy or if you're struggling with an open relationship It's a fascinating book and a great insight into all the emotions that go on in this particular author's mind He also goes to therapy, sex therapy, sex and love therapy And in that process there's all these issues that come up to do with his relationship with his mother, with his father They all say that, you know, all guys have mummy issues and all girls have daddy issues Well Neil Strauss, the author of the book The Truth, certainly has that And he details working through that and figuring out, you know, why his relationship with his mother influenced him so much In his choice of mate or his womanizing ways in his adult life It's a fascinating way to look at life or a fascinating insight into your own relationship with your parents As you figure out, like, we're all kind of messed up one way or the other Even if we had, like, really great parents you raised as well, there's still some kind of issue Like, how they raised us still affects us and still affects the types of relationships that we have later on in life I'm certainly not a psychologist or a therapist but, you know, I have gone to therapy before And, you know, a lot of the stuff that comes up is, well, for me personally is my relationship to my mother, my relationship to my father My relationship to their relationship and how that influences you in later life And certainly in this book, The Truth, by Neil Strauss, you know, his relationship to his mother affected his inability To form long, lasting, happy, monogamous relationships with women And just, you know, reading about him deconstructing that, like deconstructing why that is Is, you know, he went out and interviewed evolutionary psychologists People like Helen Fisher, who's pretty much renowned as, like, the world's leading expert on love He interviewed relationship experts, he had his brain put under a CAT scan Or maybe it wasn't a CAT scan, I think it was, they hooked nodes up to his brain To sort of track his brain when he was thinking about titillating stuff like sex and different women and then pain and struggle And they really just monitored his mind or his brain, if you like, to see what kind of activity was going on You know, when he was thinking about certain things to do with relationships So really interesting stuff, I'll read it just a couple of other little notes here He's saying here, intimacy problems come from a lack of self-love Someone who fears intimacy thinks unconsciously, if you knew who I actually was, you'd leave me When a love avoidant and a love addict begin a relationship, a predictable pattern occurs The avoidant gives and gives, sacrificing his own needs, but it's never enough for the love addict So the avoidant grows resentful and seeks an outlet outside of the relationship But at the same time, feels too guilty to stop taking care of the needy person And so forth and so forth, so it's pretty good stuff Let me just read some more insightful stuff at the end I think that it's, let's have a look here If two people are emotionally healthy adults, then there's no dilemma that they can't work out together They're not going to even notice each other aging, but just getting happier Ah, that's nice, isn't it? And he talks about his most successful relationship in which he's honest about everything And so is she, there are no secrets, so we just discuss things like we should have in the first place Yeah, and then if he's talking about if people are having sex problems Then the problem isn't actually the sex, it's the relationship between the people having it So there you go, there's a few little notes in there Definitely worth reading, check out the book The Truth by Neil Strauss The New York Times bestselling author of the game He's now a 47 year old man, I think So if you want to see what happened to him, whether he's still a player Or whether he's married, whether he's married with a kid Then you'll definitely have to read the book, or if you don't want to do that You can just google his name and see what ended up happening But yeah, check it out The Truth by Neil Strauss How do you make a better group of friends? Well, here's how you do it You put yourself in environments of people who are doing exactly the same